Comprehensive Genomic Profiling with FoundationOne® Guides Targeted Therapeutic Choices and Clinical Responses in Challenging Biliary Tract Cancers
Given the limited treatment options and poor prognosis of patients with
advanced biliary tract cancers and the diversity of clinically relevant
alterations identified, comprehensive genomic profiling appears to have
significant potential to maximize the identification of new treatment
paradigms and address an unmet clinical need for this devastating
disease. These data, including select case studies highlighting clinical
benefit in patients, were presented today in an oral presentation at the
"Biliary tract cancers are often not diagnosed until advanced stage disease, and unfortunately, many are refractory to conventional therapies, such as radiation treatment and chemotherapy, making them difficult to treat," said Dr. Javle. "These data present a new and critical understanding of the genomic alterations that are frequently present in biliary tract cancers, and highlight their heterogeneity. The identification of targetable genomic alterations is one of the most significant clinical advances in management of these cancers, particularly in the case of cholangiocarcinoma."
Key Data Highlights:
- A 67-year-old male with IHCCA had progressed on conventional chemotherapy. FoundationOne detected a BRAF mutation, and after eight weeks of BRAF inhibitor therapy, his liver metastases decreased in size. The metastases continued to decrease after an additional eight weeks of treatment.
- A 71-year-old female with metastatic GBCA was found to harbor a FGFR3-TACC3 fusion and was treated with dovitinib therapy. After four months, CT images demonstrate disease stabilization.
- A 64-year-old female with recurrent GBCA was found to have amplification of ERBB2 and was given trastuzumab and chemotherapy. After eight months of treatment, her tumors remain stable.
- A 67-year-old woman with GBCA developed liver metastases, and FoundationOne revealed amplification of EGFR, amplification of CCND1, and mutations in PIK3CA and TP53. She was given erlotinib in combination with systemic therapy, resulting in a reduction in tumor size.
Further, results of comprehensive genomic profiling showed the following:
- IHCCA, EHCCA and GBCA share frequent genomic alterations in cell cycle regulation (CDKN2B) and chromatin remodeling (ARID1A).
- IHCCA is further characterized by FGFR fusions, IDH1/2 substitutions, BRAF substitutions and MET amplification with a low KRAS mutation frequency.
- EHCCA and GBCA have frequent ERBB2 amplifications (GBCA > EHCCA) and PIK3CA/MTOR pathway alterations.
- KRAS mutation frequency is high in EHCCA and low in GBCA.
- In the case of some mutations, including KRAS, BAP1 and FGFR, there is a correlation with cancer prognosis. This has important implications regarding the choice of therapy.
"This study is unique and encouraging both in the understanding of
unique genomic drivers across broad biliary tract cancers and for the
identification of several targeted therapies with the potential to
deliver improved outcomes," said
Cautionary Note Regarding Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the ability of FoundationOne to identify clinically relevant genomic alterations, the benefits to patients of comprehensive genomic profiling of their tumors, the utility of FoundationOne in informing treatment of certain patient populations, the ability of FoundationOne to affect the prognosis, treatment or diagnosis of cancer patients, and clinical data related to FoundationOne. All such forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include the risks that Foundation Medicine's products will not be able to identify genomic alterations in the same manner as prior clinical data; and the risks described under the caption "Risk Factors" in Foundation Medicine's Annual Report on Form 10-K for the year ended December 31, 2014, which is on file with the Securities and Exchange Commission, as well as other risks detailed in Foundation Medicine's subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Foundation Medicine undertakes no duty to update this information unless required by law.
News Provided by Acquire Media